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Introduction
Perfluoroalkyl acids (PFAAs) are human-made 
chemicals found in various products, for 
example, food items and packaging, pots and 
pans, and textiles such as carpets, furniture, 
shoes, and clothing (Kantiani et al. 2010). 
Specific PFAAs [perfluorooctane sulfonate 
(PFOS) and perfluorooctanoic acid (PFOA)] 
have been voluntarily phased out or regulated 
in some parts of the world (Environment 
Canada 2010; European Parliament 2006; 
UNEP 2009; U.S. EPA 2000, 2006), and 
these compounds have to some extent been 
replaced by novel, similar compounds.
PFAAs accumulate in the human body 
(Butenhoff et al. 2006) and are persistent in 
the environment. Some have been shown to 
cross the placenta (Fei et al. 2007; Inoue et al. 
2004; Kim et al. 2011; Midasch et al. 2007), 
and it has been hypothesized that they may 
affect fetal growth and development, possibly 
due to interaction with the peroxisome 
proliferator-activated receptor alpha (Abbott 
2009), estrogen biosynthesis or interaction with 
receptors in vitro (Benninghoff et al. 2011; Du 
et al. 2013; Henry and Fair 2011; Kjeldsen and 
Bonefeld-Jørgensen 2013), thyroid hormone 
signaling (Du et al. 2013; Wang et al. 2013; 
Thibodeaux et al. 2003; Lau et al. 2003; Long 
et al. 2013; Inoue et al. 2004; Kim et al. 2011), 
or lipid metabolism (Apelberg et al. 2007; 
Thibodeaux et al. 2003). It is also plausible that 
exposures could affect the mother’s appetite 
and food intake, or have direct effects on 
placental growth and/or function.
In animals, several studies have found lower 
birth weight with exposure to PFOS (Luebker 
et al. 2005; Thibodeaux et al. 2003), PFOA 
(Koustas et al. 2014), and perfluoro undecanoic 
acid (PFUnA) (Takahashi et al. 2014). 
However, exposure levels were higher than 
average environmental exposures in humans. 
Epidemiological studies have investigated the 
association between exposure to PFOS and 
PFOA and birth weight or related outcomes 
(Apelberg et al. 2007; Arbuckle et al. 2013; 
Chen et al. 2012; Darrow et al. 2013; Fei et al. 
2007; Hamm et al. 2010; Inoue et al. 2004; 
Kishi et al. 2015; Lee et al. 2013; Maisonet 
et al. 2012; Monroy et al. 2008; Robledo et al. 
2015; Stein et al. 2009; Washino et al. 2009; 
Whitworth et al. 2012b; Wu et al. 2012). 
Even though most studies indicated an asso-
ciation with lower birth weight, in particular 
for PFOA, many studies had limited power 
and thus low precision due to small sample 
sizes (Bach et al. 2015). Few small studies (all 
with < 500 participants) investigated other 
PFAAs such as perfluorononanoic acid [PFNA 
(Arbuckle et al. 2013; Chen et al. 2012; 
Monroy et al. 2008; Robledo et al. 2015)], 
PFUnA (Chen et al. 2012), perfluorohexane 
sulfonate [PFHxS (Arbuckle et al. 2013; 
Hamm et al. 2010; Lee et al. 2013; Maisonet 
et al. 2012; Monroy et al. 2008)], perfluoro-
decanoic acid [PFDA (Robledo et al. 2015)], 
and perfluorooctane sulfonamide (Robledo 
et al. 2015) and found no consistent associa-
tions. To our knowledge, the present study is 
the largest to address PFAAs other than PFOS 
and PFOA to date. We aimed to examine the 
association between maternal serum levels of 
several PFAAs and birth weight, birth length, 
and head circumference at birth in a large 
sample of pregnant women exposed to present 
(2008–2013) population levels of PFAAs. 
Additionally, we aimed to investigate the asso-
ciation between PFAAs and gestational age at 
birth and preterm birth.
Methods
The Aarhus Birth Cohort and 
Biobank
Annually, approximately 4,500 women give 
birth at the Department of Obstetrics and 
Gynecology, Aarhus University Hospital, 
Denmark. The ongoing Aarhus Birth Cohort 
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Background: Previous studies indicated an association between intrauterine exposure to 
perfluoro octane sulfonate (PFOS) or perfluorooctanoate (PFOA) and lower birth weight. However, 
these perfluoroalkyl acids (PFAAs) have to some extent been substituted by other compounds on 
which little is known.
oBjectives: We investigated the association between specific PFAAs and birth weight, birth length, 
and head circumference at birth.
Methods: We studied 1,507 mothers and their children from the Aarhus Birth Cohort (2008–2013). 
Nulliparous women were included during pregnancy, and serum levels of 16 PFAAs were measured 
between 9 and 20 completed gestational weeks (96% within 13 weeks). For compounds with quan-
tifiable values in > 50% of samples (7 compounds), we report the associations with birth weight, 
birth length, and head circumference at birth determined by multivariable linear regression.
results: Estimated mean birth weights were lower among women with serum perfluorohexane 
sulfonate, perfluoroheptane sulfonate, and PFOS concentrations above the lowest exposure quartile, 
but we found no consistent monotonic dose–response patterns. These associations were stronger 
when the population was restricted to term births (n = 1,426). For PFOS, the birth weight esti-
mates for the highest versus lowest quartile were –50 g (95% CI: –123, 23 g) in all births and –62 g 
(95% CI: –126, 3 g) in term births. For the other PFAAs, the direction of the associations was 
inconsistent, and no overall association with birth weight was apparent. No PFAAs were associated 
with birth length or head circumference at birth.
conclusions: Overall, we did not find strong or consistent associations between PFAAs and birth 
weight or other indices of fetal growth, though estimated mean birth weights were lower among 
those with exposures above the lowest quartile for some compounds.
citation: Bach CC, Bech BH, Nohr EA, Olsen J, Matthiesen NB, Bonefeld-Jørgensen EC, Bossi R, 
Henriksen TB. 2016. Perfluoroalkyl acids in maternal serum and indices of fetal growth: the Aarhus 
Birth Cohort. Environ Health Perspect 124:848–854; http://dx.doi.org/10.1289/ehp.1510046
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(ABC) was established in 1989 and contains 
self-administered questionnaire data from 
pregnant women who plan to give birth at 
the hospital. Most women complete the ques-
tionnaire at approximately 12 weeks of gesta-
tion. The cohort also contains information 
about birth outcomes collected by clinical 
staff (attending midwives) immediately after 
delivery using a structured birth registration 
form. Trained research midwives validated 
birth data until January 2013, and after this 
date the authors reviewed the registry records. 
So far, the cohort contains information on 
> 100,000 women (Larsen et al. 2013).
A biobank was added to the cohort in 
2008 and contains blood samples from 
pregnant women, their partners, and umbil-
ical cord material (Mortensen et al. 2013). 
Most maternal blood samples were obtained 
at approximately gestational week 12. All 
samples were processed within 2 hr and stored 
at –80°C until further analysis. All participants 
provided written informed consent accepting 
that blood samples are stored in a biobank, 
that the questionnaire data are stored electron-
ically, and that all information can be used 
for future research approved by the proper 
authorities (Mortensen et al. 2013). Currently, 
the biobank contains blood samples from 
> 10,000 women.
Selection of Participants
For this study, women in the cohort were 
eligible if they donated a blood sample 
between 9 and 20 completed gestational 
weeks, gave birth to a live-born, singleton 
neonate, and were nulliparous. From the 
women who fulfilled these criteria (n = 2,853) 
we randomly sampled 1,533 women recruited 
during 2008–2013 (220–290 participants 
annually). Of these women, 1,507 (98%) 
had complete data on exposure, birth weight, 
and covariates and were included in the final 
study population. Regarding birth length, 
1,499 (98%) participants were included, 
and for head circumference, 1,494 (97%) 
participants were included in the analyses. 
Approval was obtained from the Danish Data 
Protection Agency (reference 2012-41-1288), 
and the data collection was accepted by the 
Danish National Committee on Health 
Research Ethics (reference M-20110054).
Exposure Assessment
We measured the levels of 16 PFAAs in 
maternal serum and included compounds 
where at least 50% of the samples were above 
the lower limit of quantification (LOQ) 
(Table 1). PFAA analysis was performed at the 
Department of Environmental Science, Aarhus 
University, by use of high performance liquid 
chromatography–tandem mass spectrometry 
after solid phase extraction (Liew et al. 2014).
Outcomes
The outcomes available in the cohort included 
birth weight (continuous and z-score), birth 
length, and head circumference at birth. 
z-Scores were calculated by standardization 
of birth weight for gestational age according 
to the most recent (1996) Scandinavian fetal 
reference (Marsál et al. 1996). Furthermore, we 
studied the gestational age at birth and the odds 
for preterm birth (birth before 37 weeks and 
0 days of gestation). Gestational age at birth 
was determined by first trimester ultrasound 
measurements. We identified no implausible 
values of gestational age at birth (< 24 weeks 
or > 45 weeks). We identified birth weight 
and gestational age mismatches (Alexander 
et al. 1996), and participants with implausible 
combinations (n = 5) were excluded from 
the analyses of birth weight along with six 
 participants with missing birth weight.
Statistical Analysis
We performed multivariable linear regres-
sion with robust standard errors (Huber–
White sandwich estimator) to estimate the 
association between individual PFAAs and 
continuous birth weight and birth weight 
z-scores, birth length, head circumference 
at birth, and gestational age at birth. The 
association between levels of PFAAs and 
preterm birth was analyzed by logistic regres-
sion. We substituted PFAA values below the 
LOQ with the LOQ divided by the square 
root of 2. Levels of PFAAs were divided into 
quartiles with the lowest category used as 
reference. Moreover, we assessed the associa-
tions between continuous exposure measures 
and the above-mentioned outcomes. The 
continuous exposure measures were rescaled 
to assess the change in outcomes with a 
0.1-ng/mL increase in PFAA levels because 
most of the compounds had median values 
< 1 ng/mL. To enhance comparability of 
individual PFAAs within our study, we also 
modeled estimates per interquartile range 
of exposure. In addition, PFAA levels were 
modeled by the use of restricted cubic splines 
with prespecified knots according to the 
quartile boundaries for each PFAA.
We identified covariates to include in the 
analyses by directed acyclic graphs (DAGs) 
(see Figures S1 and S2). The analyses were 
adjusted for maternal age (continuous), 
maternal prepregnancy body mass index [BMI 
(continuous)], and maternal level of educa-
tion (four categories). Furthermore we condi-
tioned on parity by restricting to nulliparous 
women. Information on maternal age and 
parity was available in the birth registration 
form, and information on BMI and maternal 
level of education was extracted from the 
questionnaire. There were no missing values 
for maternal age. Few values were missing for 
BMI (n = 11) and level of education (n = 4).
In a secondary analysis, we included gesta-
tional age (continuous) in the birth weight 
model in addition to the other covariates. 
We did this to compare our findings with the 
existing literature, even though we are aware 
of the caveats of adjustment for a potential 
intermediate (Wilcox et al. 2011). These 
considerations apply to birth weight z-scores as 
well. We also restricted the analyses to children 
born at term (≥ 37 weeks of gestation). Due to 
previous reports on sex differences concerning 
the investigated association (Andersen et al. 
2010; Maisonet et al. 2012; Robledo et al. 
2015; Washino et al. 2009), we performed the 
analyses of birth weight separate for each sex, 
as well as pooled. We examined the impor-
tance of the gestational age at blood draw by 
restriction to participants who gave a blood 
sample within 13 completed gestational weeks 
[n = 1,440 (96%)]. STATA statistical software 
version 12 (StataCorp, College Station, TX, 
USA) was used for all the statistical analyses.
Results
For seven of the measured PFAAs, more 
than 50% of the samples had concentra-
tions above the lower limit of quantifica-
tion [PFHxS, perfluoroheptane sulfonate 
(PFHpS), PFOS, PFOA, PFNA, PFDA, and 
Table 1. Perfluoroalkyl acid abbreviations, limits of quantification (LOQ), levels above the LOQ, and exposure distributions for included compounds measured in 
1,507 serum samples from the Aarhus Birth Cohort, 2008–2013.
Full name of PFAA Abbreviation LOQ % above LOQ Median (IQR) Quartile 1 Quartile 2 Quartile 3 Quartile 4
Perfluorohexane sulfonate PFHxS 0.08 99.9 0.5 (0.4–0.6) < LOQ–0.36 0.37–0.47 0.48–0.63 0.64–6.82
Perfluoroheptane sulfonate PFHpS 0.11 76 0.2 (0.1–0.2) < LOQ–0.11 0.12–0.16 0.17–0.21 0.22–1.16
Perfluorooctane sulfonate PFOS 0.28 99.9 8.3 (6.0–10.8) < LOQ–6.02 6.03–8.29 8.30–10.80 10.81–36.10
Perfluorooctanoic acid PFOA 0.20 99.9 2.0 (1.5–2.6) < LOQ–1.53 1.54–2.02 2.03–2.64 2.65–15.10
Perfluorononanoic acid PFNA 0.27 99 0.8 (0.6–1.0) < LOQ–0.60 0.61–0.75 0.76–0.97 0.98–4.69
Perfluorodecanoic acid PFDA 0.09 99 0.3 (0.2–0.4) < LOQ–0.24 0.25–0.31 0.32–0.42 0.43–2.87
Perfluoroundecanoic acid PFUnA 0.15 87 0.3 (0.2–0.4) < LOQ–0.20 0.21–0.29 0.30–0.44 0.44–2.47
Abbreviations: IQR, Interquartile range; PFAA, perfluoroalkyl acid. 
All concentrations are in nanograms per milliliter.
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PFUnA]. LOQ, levels above the LOQ, and 
distributions of the included PFAAs are listed 
in Table 1, and corresponding information 
regarding the excluded compounds is listed 
in Table S1. Pearson’s correlations for the 
seven included PFAAs are shown in Table S2. 
The two PFAAs with the highest correlation 
were PFNA and PFDA (Pearson’s correla-
tion = 0.85), and the lowest correlation was 
found for PFUnA and PFHxS (Pearson’s 
correlation = 0.14).
Women with exposure levels in the higher 
quartiles were slightly older than those with 
exposure levels in the lower quartiles—the 
median ages were 29 years in the lowest quar-
tiles and 30–31 years in the highest (Table 2). 
Maternal prepregnancy BMI did not differ 
according to exposure levels. For women with 
the three higher levels of education, there 
was not much difference between exposure 
distributions, but for the group of women 
with the lowest educational level, 38–50% 
of women had exposure levels in the lowest 
PFAA quartiles.
For three perfluoroalkane sulfonic acids 
(PFHxS, PFHpS, and PFOS) estimated 
mean birth weights were lower for all quar-
tiles above the first quartile (Table 3). Only 
PFHxS showed some indication of a mono-
tonic dose–response relationship with birth 
weight. Further adjustment for gestational age 
did not change the results in any consistent 
direction, but the associations for PFHxS, 
PFHps, and PFOS were stronger in term 
births (n = 1,426). Continuous exposure 
measures of these compounds were not 
consistently associated with lower estimated 
mean birth weights.
No obvious association was found 
between PFOA, PFNA, PFDA, and PFUnA 
and birth weight (Table 3) regardless of 
whether exposures were modeled as contin-
uous or categorical variables. For individual 
compounds the direction of the estimates was 
not consistent in each quartile, and no dose–
response relationships were evident.
Restricted cubic splines of the asso-
ciations between PFAAs and birth weight are 
presented in Figure S3. In general these did 
not identify any clear thresholds nor did they 
indicate monotonic dose–response patterns.
The associations between PFAA exposure 
and birth weight did not differ substantially 
between boys and girls for most compounds 
(Table 4). For PFNA and PFDA, estimated 
mean birth weights were lower for girls than 
for boys for quartiles above the first quartile, 
but in girls there was no monotonic dose–
response pattern, and some of the apparent 
sex differences were attributable to higher 
estimated mean birth weight in boys with 
exposures above the lowest quartile.
Estimates for the association between 
PFAA exposures and birth length and head 
circumference at birth were all close to zero 
(see Table S3). There was no obvious associa-
tion between PFAA exposure and gestational 
age at birth or preterm birth (see Table S4). 
The levels of PFAAs were similar in samples 
taken before and after 13 gestational weeks 
(data not shown), and the exclusion of 67 
participants with a blood sample drawn after 
13 completed gestational weeks did not 
change the results (data not shown).
Discussion
Overall, we found weak and inconsistent asso-
ciations between PFAA exposures and birth 
weight, birth length, and head circumfer-
ence at birth. Independent of offspring sex, 
estimated mean birth weights were lower in 
quartiles above the lowest quartile of three 
perfluoroalkane sulfonic acids, without clear 
monotonic dose–response patterns, whereas 
PFNA and PFDA tended to be associated with 
lower birth weight in girls only. However, the 
sex-specific estimates were less precise than the 
estimates from the complete population.
Quite a few studies have investigated the 
association between PFAAs and infant size 
at birth. PFAAs were measured in plasma or 
serum from maternal blood before concep-
tion, during pregnancy, or at birth, or in 
umbilical cord blood; and exposures were 
modeled as different continuous or categorical 
variables, which have made comparison of 
the results cumbersome. Also, the studies 
controlled for different factors (Bach et al. 
2015). Nine studies investigated the asso-
ciation between PFOA and birth weight 
(Apelberg et al. 2007; Chen et al. 2012; 
Darrow et al. 2013; Fei et al. 2007; Hamm 
et al. 2010; Kishi et al. 2015; Maisonet et al. 
2012; Robledo et al. 2015; Washino et al. 
2009), and all found lower estimated mean 
birth weights with increasing exposure levels 
even though the magnitude and precision of 
the estimates varied substantially. Seven of 10 
studies found tendencies towards lower birth 
weight with higher PFOS levels (Apelberg 
et al. 2007; Chen et al. 2012; Darrow et al. 
2013; Fei et al. 2007; Hamm et al. 2010; 
Table 2. Maternal characteristics according to early pregnancy levels of perfluoroalkyl acids in 1,507 
mothers from the Aarhus Birth Cohort, 2008–2013.
PFAA
Age (years)  
[median (IQR)]
Prepregnancy BMI (kg/m2) 
[median (IQR)]
Education (%)
1 (n = 42) 2 (n = 439) 3 (n = 580) 4 (n = 446)
PFHxS
Q1 29 (27–31) 22 (20–25) 50 27 27 19
Q2 29 (27–31) 22 (21–25) 19 24 26 25
Q3 30 (27–32) 22 (21–25) 21 27 23 25
Q4 31 (29–33) 22 (20–25) 10 23 24 31
PFHpS
Q1 29 (27–32) 22 (20–24) 48 23 26 24
Q2 29 (27–32) 22 (20–24) 14 28 25 26
Q3 29 (27–32) 22 (20–25) 21 24 26 22
Q4 30 (28–33) 22 (21–25) 17 24 22 28
PFOS
Q1 29 (27–32) 22 (20–25) 45 25 27 22
Q2 29 (27–32) 22 (20–25) 19 25 25 24
Q3 29 (27–32) 22 (20–24) 22 27 23 29
Q4 30 (28–32) 22 (21–25) 14 23 25 25
PFOA
Q1 29 (27–32) 22 (21–26) 43 23 27 23
Q2 29 (27–32) 22 (20–24) 28 25 26 26
Q3 29 (27–31) 22 (20–25) 10 27 23 25
Q4 30 (28–32) 22 (21–25) 19 25 24 26
PFNA
Q1 29 (27–32) 22 (20–25) 48 26 25 21
Q2 30 (28–32) 22 (21–25) 17 26 25 27
Q3 30 (27–32) 22 (20–24) 10 24 24 27
Q4 30 (28–32) 22 (21–25) 26 24 26 24
PFDA
Q1 29 (27–32) 22 (20–25) 38 27 27 20
Q2 29 (27–31) 22 (21–25) 19 25 26 24
Q3 30 (27–33) 22 (20–25) 10 25 23 29
Q4 30 (28–32) 22 (20–24) 33 23 24 28
PFUnA
Q1 29 (27–32) 22 (21–26) 48 30 27 18
Q2 29 (27–32) 22 (20–25) 19 25 26 22
Q3 30 (27–32) 22 (20–25) 17 23 23 31
Q4 30 (28–32) 22 (20–24) 17 22 24 29
Abbreviations: IQR, interquartile range; PFAA, perfluoroalkyl acid; Q, quartile. For specific PFAA abbreviations see 
Table 1. Definitions of highest completed maternal education: 1. Municipal primary and lower secondary school; 2. 
upper secondary school, or 1–2 years of vocational training; 3. additional 3–4 years of education, e.g., Bachelor’s 
degree; 4. > 4 additional years of education, e.g., Master’s degree.
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Inoue et al. 2004; Kishi et al. 2015; Maisonet 
et al. 2012; Robledo et al. 2015; Washino 
et al. 2009). Compared with some previous 
studies, we report lower serum levels of PFOS 
(Darrow et al. 2013; Fei et al. 2007; Lee et al. 
2013; Maisonet et al. 2012; Monroy et al. 
2008) and PFOA (Darrow et al. 2013; Fei 
et al. 2007; Maisonet et al. 2012; Wu et al. 
2012). For instance, the mean level of PFOA 
was 5.6 ng/mL in a previous Danish study 
(1996–2002) by Fei et al. (2007) compared 
with 2.2 ng/mL in the present study. In the 
study by Fei et al. (2007), the mean level 
of PFOS was 35.3 ng/mL compared with 
8.9 ng/mL in the present study. This may be 
attributable to a decreasing exposure trend 
over time. If a threshold value of exposure 
exists, this may partly explain the lack of an 
association between PFOA and birth weight, 
birth length, and head circumference at birth 
in the present study. It is possible that regula-
tory measures might have decreased exposure 
sources sufficiently, perhaps to an extent 
that PFOA does not pose a potential threat 
to perinatal health. Thus, the results of the 
present study are largely reassuring. However, 
in accordance with other studies, the present 
results suggest an association between PFOS 
and lower birth weight. Other compounds, 
such as PFHxS and PFHpS, were also asso-
ciated with lower birth weight. If an asso-
ciation between PFAAs and birth weight is 
mediated by changes in the sex hormone 
homeostasis, this may explain the somewhat 
different associations that we found according 
to offspring sex for PFNA and PFDA, but 
Table 3. Maternal levels of perfluoroalkyl acids and birth weight in 1,507 children from the Aarhus Birth Cohort, 2008–2013.
PFAA/exposure scale
Birth weight (g) Birth weight z-score
Mean ± SD Crude
Adjusteda  
(95% CI)
Adjustedb  
(95% CI)
Restrictedc  
(95% CI) Crude
Adjusteda  
(95% CI)
PFHxS
Q1 3,460 ± 556 Reference Reference Reference Reference Reference Reference
Q2 3,452 ± 460 –9 –15 (–87, 57) –11 (–67, 44) –41 (–105, 24) 0.00 –0.01 (–0.15, 0.12)
Q3 3,436 ± 504 –24 –25 (–100, 50) –21 (–79, 37) –34 (–101, 32) –0.04 –0.03 (–0.17, 0.11)
Q4 3,424 ± 511 –37 –29 (–106, 47) –49 (–109, 11) –49 (–118, 19) –0.13 –0.11 (–0.25, 0.03)
Per IQR (0.3 ng/mL) –9 –7 (–28, 14) –13 (–30, 3) –11 (–32, 9) –0.04 –0.03 (–0.07, 0.01)
Per 0.1 ng/mL –3 –2 (–10, 5) –5 (–11, 1) –4 (–12, 3) –0.01 –0.01 (–0.03, 0.00)
PFHpS
Q1 3,473 ± 509 Reference Reference Reference Reference Reference Reference
Q2 3,418 ± 540 –56 –52 (–126, 21) –20 (–75, 35) –46 (–109, 17) –0.05 –0.04 (–0.17, 0.10)
Q3 3,446 ± 478 –27 –34 (–105, 36) –50 (–107, 6) –56 (–118, 7) –0.10 –0.11 (–0.24, 0.02)
Q4 3,436 ± 504 –38 –42 (–115, 31) –43 (–100, 14) –63 (–129, 2) –0.10 –0.10 (–0.23, 0.04)
Per IQR (0.1 ng/mL) –8 –12 (–40, 17) –17 (–40, 6) –23 (–50, 4) –0.03 –0.04 (–0.09, 0.02)
Per 0.1 ng/mL –7 –11 (–37, 16) –15 (–36, 5) –21 (–45, 3) –0.03 –0.04 (–0.09, 0.02)
PFOS
Q1 3,481 ± 520 Reference Reference Reference Reference Reference Reference
Q2 3,397 ± 518 –84 –86 (–159, –13) –66 (–122, –11) –93 (–157, –29) –0.15 –0.15 (–0.29, –0.02)
Q3 3,461 ± 486 –20 –21 (–91, 48) –30 (–86, 26) –50 (–113, 13) –0.07 –0.06 (–0.19, 0.07)
Q4 3,431 ± 510 –50 –50 (–123, 23) –58 (–105, 8) –62 (–126, 3) –0.11 –0.11 (–0.25, 0.02)
Per IQR (4.8 ng/mL) –1 –2 (–30, 26) –8 (–30, 14) –14 (–40, 11) –0.02 –0.02 (–0.07, 0.04)
Per 0.1 ng/mL 0 0 (–1, 1) 0 (–1.0) 0 (–1, 0) 0.00 0.00 (0.00, 0.00)
PFOA
Q1 3,441 ± 536 Reference Reference Reference Reference Reference Reference
Q2 3,419 ± 522 –22 –1 (–75, 74) 3 (–54, 59) –36 (–101, 30) –0.04 0.009 (–0.13, 0.14)
Q3 3,458 ± 488 17 28 (–45, 102) 15 (–42, 72) –7 (–73, 58) 0.01 0.04 (–0.09, 0.17)
Q4 3,455 ± 488 13 26 (–47, 98) 9 (–47, 64) 4 (–59, 67) –0.005 0.03 (–0.10, 0.16)
Per IQR (1.1 ng/mL) 19 21 (–1, 44) 7 (–10, 23) 13 (–6, 33) 0.01 0.02 (–0.02, 0.06)
Per 0.1 ng/mL 2 2 (–1, 4) 1 (–1, 2) 1 (–1, 3) 0.00 0.00 (0.00, 0.00)
PFNA
Q1 3,458 ± 544 Reference Reference Reference Reference Reference Reference
Q2 3,452 ± 496 –6 –12 (–85, 61) –20 (–77, 37) –26 (–92, 40) –0.02 –0.03 (–0.17, 0.10)
Q3 3,391 ± 501 –67 –63 (–137, 11) –43 (–100, 14) –72 (–137, –6) –0.10 –0.08 (–0.22, 0.05)
Q4 3,471 ± 490 14 11 (–62, 84) 3 (–54, 61) 10 (–55, 75) 0.03 0.02 (–0.11, 0.16)
Per IQR (0.4 ng/mL) 16 15 (–7, 38) 8 (–9, 25) 11 (–9, 31) 0.02 0.02 (–0.02, 0.06)
Per 0.1 ng/mL 4 4 (–2, 10) 2 (–2, 7) 3 (–2, 9) 0.01 0.01 (0.00, 0.02)
PFDA
Q1 3,461 ± 554 Reference Reference Reference Reference Reference Reference
Q2 3,432 ± 492 –29 –34 (–107, 39) –45 (–103, 13) –55 (–120, 11) –0.09 –0.10 (–0.24, 0.04)
Q3 3,411 ± 506 –50 –44 (–119, 31) –55(–113, 2) –52 (–117, 13) –0.15 –0.13 (–0.26, 0.01)
Q4 3,468 ± 480 7 17 (–56, 90) 2 (–55, 59) 4 (–60, 69) –0.01 0.02 (–0.12, 0.15)
Per IQR (0.2 ng/mL) 11 15 (–6, 37) 9 (–7, 24) 13 (–6, 31) 0.01 0.02 (–0.01, 0.06)
Per 0.1 ng/mL 6 9 (–3, 21) 5 (–4, 13) 7 (–3, 17) 0.01 0.01 (–0.01, 0.03)
PFUnA
Q1 3,449 ± 532 Reference Reference Reference Reference Reference Reference
Q2 3,439 ± 510 –10 3 (–71, 76) –3 (–61, 55) 4 (–60, 69) –0.04 –0.007 (–0.15, 0.13)
Q3 3,459 ± 513 10 29 (–46, 105) 17 (–42, 76) 24 (–43, 91) –0.02 0.03 (–0.11, 0.18)
Q4 3,425 ± 480 –24 8 (–65, 81) –13 (–72, 45) –15 (–81, 51) –0.11 –0.03 (–0.17, 0.11)
Per IQR (0.2 ng/mL) –9 0 (–21, 21) –5 (–22, 11) –8 (–27, 11) –0.03 –0.01 (–0.05, 0.03)
Per 0.1 ng/mL –4 0 (–8, 9) –2 (–9, 5) –3 (–11, 5) –0.01 0.00 (–0.02, 0.01)
Abbreviations: IQR, interquartile range; Q, quartile. For PFAA abbreviations see Table 1.
aAdjusted for maternal age, prepregnancy BMI and educational level. bAdditionally adjusted for gestational age (continuous). cAdjusted as model A and restricted to term births 
(> 37 gestational weeks and 0 days). Adjustment for gestational age among infants born at term did not changes the results (data not shown).
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these differences may also be attributable to 
statistical imprecision. Compounds other 
than PFOS and PFOA have been studied to a 
lesser extent, are currently not regulated, and 
thus need further investigation.
We studied women who were nulliparous 
at inclusion, gave birth to a live-born child, 
provided blood samples, and completed a 
questionnaire. This may influence the validity 
and generalizability of our results. Selection 
bias due to nonresponse may not be very likely 
since participants were unaware of individual 
exposure levels (at any time) as well as the 
outcomes at the time of inclusion. However, it 
cannot be ruled out that the selection of study 
participants may have been associated with 
both exposure levels and the outcomes.
A few studies investigated the association 
between PFAAs and fecundability (Buck Louis 
et al. 2013; Fei et al. 2009; Jørgensen et al. 
2014; Vélez et al. 2015; Vestergaard et al. 
2012; Whitworth et al. 2012a), miscarriage 
(Darrow et al. 2014; Jensen et al. 2015; Savitz 
et al. 2012a; Stein et al. 2009), and still-
birth (Savitz et al. 2012a, 2012b) and found 
inconsistent results. Survival until birth may 
be less likely to occur among smaller fetuses, 
and if PFAA exposure is also associated with 
a decreased chance of live birth, restriction of 
the study population to live births only may 
have introduced selection bias which poten-
tially attenuated a possible association between 
PFAAs and lower birth weight (Liew et al. 
2015). However, the magnitude of a possible 
bias is largely unknown, and the bias relies on 
the strong assumption of very strong associa-
tions between PFAA exposure and a decreased 
chance of live birth. Adjustment for common 
causes of low birth weight and fetal survival, 
such as maternal age, BMI, and educational 
level, would have reduced a possible live birth 
bias (Liew et al. 2015).
Accurate exposure assessment and the 
use of multiple exposure scales (continuous, 
categorical, splines) were strengths of our 
study. We chose to use the same contin-
uous exposure scales for all compounds 
even though an increase of 0.1 ng/mL was 
a large increase for compounds with low 
average concentrations and a small increase 
for compounds with higher average concen-
trations such as PFOS and PFOA. To 
ease comparability for the different PFAAs 
within our study, we also used continuous 
exposures divided by the interquartile range. 
We demanded strict laboratory procedures 
from sampling to the final analysis. Limited 
time was allowed from blood sampling to 
processing and freezing, state-of-the-art labo-
ratory equipment was used, and the high 
performance  chromatography–tandem mass 
spectrometry setup was controlled using 
internal and external validation and controls. 
Objectively measured exposures such 
as PFAA levels are unlikely to be prone to 
differential measurement error. Because levels 
of PFAAs decrease throughout pregnancy 
(Glynn et al. 2012), we only included women 
who gave a blood sample before 20 completed 
gestational weeks.
Trained health care professionals systemat-
ically assessed the outcomes as part of routine 
data collection concerning all births at the 
hospital. Measurement error concerning birth 
weight, particularly differential measurement 
error, is unlikely to be of importance. 
However, birth length and head circumfer-
ence at birth may be more prone to measure-
ment error, and this might partly explain our 
close-to-null results for these outcomes.
We were able to control for the poten-
tial confounders we considered to be most 
important (see Figures S1 and S2), including 
maternal prepregnancy BMI, age, educational 
level, and parity (by restriction to first-time 
mothers). Maternal prepregnancy BMI and 
Table 4. Sex-stratified associations between levels of perfluoroalkyl acids and birth weight in 764 boys 
and 743 girls from the Aarhus Birth Cohort, 2008–2013.
PFAA/exposure scale
Birth weight in boys Birth weight in girls
Sex-exposure 
interactionb
Crude Adjusteda (95% CI) Crude Adjusteda (95% CI) Adjusteda (95% CI)
PFHxS
Q1 Reference Reference Reference Reference Reference
Q2 –14 –21 (–124, 82) 5 6 (–93, 106) 27 (–115, 170)
Q3 –31 –19 (–127, 89) –19 –21 (–123, 80) –3 (–151, 145)
Q4 –13 –16 (–125, 93) –56 –34 (–141, 73) –17 (–170, 135)
Per IQR (0.3 ng/mL) –14 –14 (–51, 22) –5 –1 (–25, 22) 13 (–30, 56)
Per 0.1 ng/mL –5 –5 (–19, 8) –2 0 (–9, 8) 5 (–11, 21)
PFHpS
Q1 Reference Reference Reference Reference Reference
Q2 –82 –69 (–178, 40) –36 –39 (–138, 60) 30 (–117, 177)
Q3 0 0 (–102, 101) –48 –60 (–153, 37) –58 (–197, 82)
Q4 –15 –16 (–123, 92) –76 –78 (–176, 20) –63 (–208, 83)
Per IQR (0.1 ng/mL) 5 4 (–35, 43) –27 –30 (–72, 12) –34 (–91, 23)
Per 0.1 ng/mL 5 4 (–32, 39) –25 –27 (–65, 11) –31 (–83, 21)
PFOS
Q1 Reference Reference Reference Reference Reference
Q2 –132 –129 (–239, –19) –37 –44 (–140, 52) 85 (–61, 231)
Q3 16 9 (–93, 110) –56 –55 (–148, 38) –63 (–201, 75)
Q4 –40 –37 (–141, 67) –73 –71 (–174, 31) –34 (–180, 112)
Per IQR (4.8 ng/mL) 25 26 (–13, 65) –32 –32 (–71, 7) –58 (–114, –3)
Per 0.1 ng/mL 1 1 (0, 1) –1 –1 (–1, 0) –1 (–2, –1)
PFOA
Q1 Reference Reference Reference Reference Reference
Q2 –35 –17 (–126, 93) –11 6 (–95, 107) 23 (–126, 172)
Q3 36 54 (–54, 163) –11 –2 (–100, 95) –56 (–202, 89)
Q4 11 21 (–84, 126) 11 22 (–79, 124) 1 (–144, 147)
Per IQR (1.1 ng/mL) 27 31 (4, 59) 1 4 (–34, 42) –27 (–74, 20)
Per 0.1 ng/mL 2 3 (0, 5) 0 0 (–3, 4) –2 (–7, 2)
PFNA
Q1 Reference Reference Reference Reference Reference
Q2 63 62 (–48, 172) –89 –97 (–193, –2) –160 (–305, –14)
Q3 20 19 (–94, 133) –131 –123 (–218, –29) –143 (–291, 5)
Q4 50 46 (–64, 155) –39 –35 (–133, 63) –81 (–228, 66)
Per IQR (0.4 ng/mL) 28 27 (–5, 59) –5 –4 (–38, 31) –31 (–78, 16)
Per 0.1 ng/mL 8 7 (–2, 16) –1 –1 (–11, 8) –9 (–22, 5)
PFDA
Q1 Reference Reference Reference Reference Reference
Q2 11 13 (–98, 124) –65 –70 (–167, 26) –84 (–230, 63)
Q3 30 38 (–73, 148) –136 –127 (–228, –26) –165 (–314, –15)
Q4 74 84 (–25, 192) –73 –58 (–156, 39) –142 (–287, 4)
Per IQR (0.2 ng/mL) 18 21 (–7, 49) –6 0 (–36, 37) –20 (–166, 25)
Per 0.1 ng/mL 10 12 (–4, 27) –3 0 (–20, 21) –11 (–37, 14)
PFUnA
Q1 Reference Reference Reference Reference Reference
Q2 –17 –12 (–124, 99) –14 0 (–97, 97) 13 (–135, 161)
Q3 7 25 (–86, 136) 2 24 (–79, 127) –1 (–152, 150)
Q4 –19 13 (–101, 127) –41 –11 (–102, 81) –24 (–169, 122)
Per IQR (0.2 ng/mL) –8 1 (–33, 35) –13 –5 (–31, 22) –6 (–49, 37)
Per 0.1 ng/mL –3 1 (–14, 15) –5 –2 (–13, 9) –2 (–20, 15)
Abbreviations: IQR, interquartile range; Q, quartile. For PFAA abbreviations, see Table 1.
aAdjusted for maternal age, prepregnancy BMI, and educational level. bDifferences in birth weight between sexes are 
based on girls compared with boys—negative estimates refer to lower birth weight estimates for girls compared with boys.
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education were self-reported and may thus 
be recorded with some error. It is debatable 
whether the slightly stronger association for 
PFHxS, PFHpS, and PFOS after adjustment 
for gestational age, restriction to term births, 
or modeling of z-scores may be attributable to 
collider stratification bias (if gestational age is 
a mediator of the association between PFAAs 
and birth weight, and any factors we did not 
account for affected both gestational age and 
birth weight, conditioning on gestational 
age may have induced a spurious association 
between PFAAs and birth weight).
Physiological phenomena in pregnancy, 
including changes in the maternal glomerular 
filtration rate (GFR) and plasma volume 
expansion, may be potentially important 
confounders if exposures are assessed in late 
pregnancy or at birth (Loccisano et al. 2013; 
Morken et al. 2014). These phenomena are 
of much larger magnitude in late than in early 
pregnancy, and the fact that we measured 
PFAA levels early is likely to have reduced 
potential confounding by these factors, which 
we did not collect information on. In previous 
studies measuring PFAAs in late pregnancy, 
or at birth, confounding by changes in GFR 
and plasma volume expansion may poten-
tially explain the associations demonstrated 
between higher levels of PFAAs and lower 
birth weight. However, in a recent review of 
the literature, we found no systematic differ-
ences in the magnitude and direction of the 
association between PFAAs and the estimated 
mean birth weight differences according to 
the timing of exposure assessment (Bach et al. 
2015). Because the causal window of exposure 
is largely unknown, the optimal timing of 
exposure assessment is unsettled. We consider 
early measurements to be preferable in order 
to limit the impact of physiological changes 
during pregnancy that may influence the 
measured exposures.
Levels of PFAA compounds are corre-
lated (see Table S2), and different PFAAs are 
likely derived from similar exposure sources. 
Biologically, it is possible that different 
PFAAs share health effects.
Conclusions
We found no strong associations between 
PFAA exposures and birth weight, birth 
length, or head circumference at birth. In 
particular, we failed to replicate the associa-
tion between PFOA and lower birth weight 
previously shown primarily in populations 
with higher exposures that were not restricted 
to nulliparous women. The estimated mean 
birth weights were lower in quartiles above the 
reference for PFOS, PFHxS, and PFHpS for 
all infants and for PFNA and PFDA in girls 
only. Most of the compounds we investigated 
have not been studied much, and more studies 
are warranted.
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